Hepion Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Net loss | $(48,926,042) | $(42,200,049) |
| Other comprehensive income (loss): | ||
| Foreign currency translation | 11,389 | (90,168) |
| Total other comprehensive income (loss) | 11,389 | (90,168) |
| Comprehensive loss | $(48,914,653) | $(42,290,217) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.